Evotec SE (NASDAQ:EVO - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $4.28, but opened at $4.10. Evotec shares last traded at $4.07, with a volume of 10,223 shares.
Analysts Set New Price Targets
A number of brokerages recently weighed in on EVO. Royal Bank of Canada reiterated an "outperform" rating on shares of Evotec in a report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, Evotec presently has an average rating of "Hold" and an average price target of $5.93.
Get Our Latest Research Report on EVO
Evotec Stock Up 5.8%
The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. The company's fifty day moving average price is $3.78 and its 200 day moving average price is $4.17.
Hedge Funds Weigh In On Evotec
A number of hedge funds and other institutional investors have recently bought and sold shares of EVO. DCF Advisers LLC lifted its holdings in shares of Evotec by 227.0% in the 1st quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock worth $2,510,000 after purchasing an additional 521,708 shares during the last quarter. ABC Arbitrage SA acquired a new stake in Evotec in the first quarter worth $260,000. Lighthouse Investment Partners LLC bought a new stake in Evotec in the fourth quarter valued at $166,000. CSS LLC IL acquired a new position in shares of Evotec during the fourth quarter valued at $50,000. Finally, Bank of America Corp DE boosted its holdings in shares of Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after acquiring an additional 9,289 shares during the period. 5.81% of the stock is currently owned by institutional investors and hedge funds.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
